Scott Naturman

Scott Naturman is a corporate partner in Hughes Hubbard’s New York office. His practice focuses on counseling clients, including public and private companies, private equity firms and emerging companies, with respect to broad spectrum of corporate transactions, including with respect to mergers and acquisitions transactions, and commercial transactions, particularly with respect to life sciences, as well corporate governance matters, including advising emerging companies on day-to-day matters. Scott has broad experience representing U.S. and international clients operating in various industries including life sciences, healthcare, technology, data, financial services, media and entertainment, energy, infrastructure, professional services, and consumer products.

His experience with respect to corporate transactions includes counseling clients in mergers, acquisitions, divestitures, private equity transactions, joint ventures, strategic alliances, and venture capital transactions, and hybrid transactions. His experience with respect to commercial transactions includes counseling clients with respect to license agreements, collaboration agreements, master service agreements, revenue share agreements, transitional service agreements, development agreements, commercialization agreements, clinical services agreements, consulting agreements, confidentiality agreements and other similar agreements. His experience with corporate governance matters includes counseling clients with respect to the assessment of transactional matters, day-to-day matters, corporate governance structures, and implementing internal restructurings.

• Representation of diversified biopharmaceutical company ANI Pharmaceuticals in its acquisition of global pharmaceutical company Alimera Sciences
• Representation of Standard Motor Products in its $388 million acquisition of Nissens Automotive, a leading European manufacturer of engine-cooling and air-conditioning products
• Representation of Newhouse family-owned media company Advance Publications Inc. and its portfolio company 1010data, a provider of enterprise analytics, in the sale of 1010data to SymphonyAI
• Representation of Cyclerion Therapeutics, Inc. in the sale of the rights to two drugs to a company newly-formed by certain existing Cyclerion shareholders and venture capital firms in exchange for cash and shares of stock in the new company
• Representation of Hyve Group, an international organizer of exhibitions and conferences, in connection with its acquisition of healthcare event company HLTH
• Representation of MSG Sports in connection with the combination of Counter Logic Gaming, of which MSG Sports previously owned a controlling interest, with NRG, a professional gaming and entertainment company. As a result of the transaction, MSG Sports now owns a noncontrolling equity interest in the larger, combined NRG/CLG company
• Representation of Greenbriar Equity Group LLC in connection with the acquisition of automotive aftermarket parts and accessories distributor JEGS High Performance
• Representation of Santander Consumer USA Holdings Inc. in its sale to parent company and majority shareholder Santander Holdings USA Inc. in a $2.5 billion deal that took the Dallas-based auto lending and consumer finance company private
• Representation of SPAC Isos Acquisition Corp. in its $2.6 billion IPO merger with Bowlero Corp. that took the world’s largest owner and operator of bowling centers public
• Representation of Mill Rock Capital in its investment in the Execu/Search Group
• Representation of Mill Rock Capital in its strategic growth investment in DRT Holdings, Inc.
• Representation of ICV in its investment in Mintz Group
• Representation of Piramal Enterprises Limited in its $950 million sale of Decision Resources Group
• Representation of Elbit in its acquisition of Sparton
• Representation of Orbia (f/k/a Mexichem) in its $1.8 billion acquisition of Netafim Ltd., a global technology and industrial company based in Israel
• Representation of TE Connectivity in a cross border, carve-out acquisition from ABB
• Representation of Johnson & Johnson in its sale of RoC Skincare
• Representation of Sensyne Health plc in its exclusive strategic collaboration with, and a $10 million equity investment in, Phesi, Inc, a U.S.-based specialist clinical trials data company, and its £27.5 million equity fundraising
• Representation of Renesas Electronics Corporation on its $4.9 billion recommended cash offer for Dialog Semiconductor PLC
• Representation of Stryker Corporation in its acquisition of Novadaq Technologies, Inc.
• Representation of Fiberon in its $470 million sale to Fortune Brands Home & Security
• Representation of Reliance Industries Limited in its $75 million acquisition of Radisys Corporation
• Representation of Illumina in its announced $1.2 billion acquisition of Pacific Biosciences
• Representation of Eisai Co., Ltd. and Eisai Inc. on the acquisition of all global development and marketing rights for the chronic weight management treatment lorcaserin hydrochloride (BELVIQ) from Arena Pharmaceuticals, Inc.
• Representation of Altice in the $1 billion co-investment by funds advised by BC Partners and Canada Pension Plan Investment Board in Cablevision Systems Corporation 
• Representation of European telecommunications company Altice S.A. in a $9.1 billion transaction to acquire a controlling stake in Suddenlink, the seventh largest cable operator in the U.S.
• Representation of Johnson & Johnson in the sale of its global Splenda business to Heartland Food Products Group and Centerbridge Partners LP
• Representation of Famy Care Limited in the $750 million sale of its women's health business to Mylan Laboratories Limited
• Representation of Gannett Broadcasting in its formation and broadcasting of the Justice Network, a digital multicast channel devoted to law enforcement-related programming
• Representation of ITOCHU Corporation and ITOCHU International Inc. in the sale of PrimeSource Building Products, Inc., a North American distributor of building materials, to Platinum Equity
• Representation of Resource America in its credit management joint venture with CVC Capital Partners
• Representation of Ascension in a $200 million investment in preferred stock of Accretive Health